El cribado fenotípico converge en la inhibición de CDK9 como estrategia terapéutica en el carcinoma de células renales de translocación
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.Los investigadores han identificado una nueva estrategia terapéutica para el carcinoma de células renales de translocación (CCRT). Dirigirse a CDK9, un regulador clave, suprimió efectivamente el crecimiento celular de tRCC al inhibir la proteína de fusión TFE3.
Área De La Ciencia
- En el campo de la oncología
- Biología molecular
- Farmacología
Sus Antecedentes
- El carcinoma de células renales por translocación (tRCC) es un cáncer renal agresivo.
- El factor de transcripción TFE3 es esencial para el tRCC pero no para las células normales, lo que lo convierte en un objetivo terapéutico desafiante.
- El dominio básico hélice-bucle-hélice (bHLH) de TFE3 es crítico para su función.
Objetivo Del Estudio
- Identificar los compuestos que modulan el TFE3 ligado a la cromatina.
- Explorar la inhibición de la CDK9 como estrategia terapéutica para el tRCC.
- Demostrar la utilidad del cribado fenotípico basado en el mecanismo.
Principales Métodos
- Evaluación fenotípica de 25.000 compuestos para la identificación de los moduladores de la TFE3 ligada a la cromatina.
- Investigó el mecanismo de acción de los compuestos identificados, incluido BRD6866.
- Se utilizaron inhibidores selectivos de CDK9, como el enitociclib, para validar los hallazgos.
Principales Resultados
- Identificado BRD6866, un compuesto que atrapa TFE3 en la cromatina y actúa como un inhibidor pan-CDK.
- Se ha demostrado que BRD6866 inhibe la CDK9, perjudicando la actividad de fusión de TFE3 y regulando a la baja los objetivos de TFE3.
- Enitociclib, un inhibidor de la CDK9, recapituló estos efectos y suprimió el crecimiento de las células tRCC.
Conclusiones
- La inhibición de la CDK9 es una estrategia terapéutica prometedora para el carcinoma de células renales de translocación.
- El cribado fenotípico basado en el mecanismo es efectivo para apuntar a objetivos terapéuticos difíciles como TFE3.
- Dirigirse al tRCC impulsado por TFE3 a través de la inhibición de CDK9 ofrece una nueva vía de tratamiento.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...